



(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/4985 (2006.01)  
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/025562

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/497,683 21 April 2023 (21.04.2023) US  
63/551,246 08 February 2024 (08.02.2024) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333  
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: ARMSTRONG, Megan K.; c/o Gilead  
Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-  
nia 94404 (US). CHIN, Elbert; c/o Gilead Sciences, Inc.,  
333 Lakeside Drive, Foster City, California 94404 (US).  
CHOU, Chienhung; c/o Gilead Sciences, Inc., 333 Lake-  
side Drive, Foster City, California 94404 (US). DEBIEN,  
Laurent P.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,  
Foster City, California 94404 (US). DENG, Yifan; c/o  
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal-  
ifornia 94404 (US). FARR, Joshua D.; c/o Gilead Sciences,

Inc., 333 Lakeside Drive, Foster City, California 94404  
(US). GUPTA, Pancham Lal; c/o Gilead Sciences, Inc.,  
333 Lakeside Drive, Foster City, California 94404 (US).  
HUNG, Chao-I; c/o Gilead Sciences, Inc., 333 Lakeside  
Drive, Foster City, California 94404 (US). JUNE, Ben-  
jamin J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,  
Foster City, California 94404 (US). MUKHERJEE,  
Prasenjit K.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,  
Foster City, California 94404 (US). NGUYEN, Shaina V.;  
c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,  
California 94404 (US). NOTTE, Gregory T.; c/o Gilead  
Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-  
nia 94404 (US). ROA, Daniel; c/o Gilead Sciences, Inc.,  
333 Lakeside Drive, Foster City, California 94404 (US).  
SCHRIER, Adam J.; c/o Gilead Sciences, Inc., 333 Lake-  
side Drive, Foster City, California 94404 (US). SPENCE,  
Katie A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,  
Foster City, California 94404 (US). YANG, Zheng-Yu; c/o  
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal-  
ifornia 94404 (US).

(74) Agent: LIU, Jiangqiong et al.; Gilead Sciences, Inc., 333  
Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: PRMT5 INHIBITORS AND USES THEREOF




FIG. 1

(57) Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*